Westpac Banking Corp acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 7,059 shares of the biopharmaceutical company’s stock, valued at approximately $4,402,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Orbimed Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $11,358,000. Lockheed Martin Investment Management Co. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $2,702,000. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $5,682,636,000. National Pension Service raised its position in Regeneron Pharmaceuticals by 29.8% in the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after purchasing an additional 82,853 shares during the period. Finally, Eurizon Capital SGR S.p.A. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $10,472,000. Institutional investors and hedge funds own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Price Performance
REGN stock opened at $834.04 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00. The stock’s 50 day moving average is $697.09 and its two-hundred day moving average is $716.73. The company has a market capitalization of $85.87 billion, a PE ratio of 20.61, a P/E/G ratio of 1.41 and a beta of 0.22.
Regeneron Pharmaceuticals Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the company. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Truist Financial upped their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $801.70.
View Our Latest Research Report on Regeneron Pharmaceuticals
Insider Activity at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $482,400. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock valued at $1,090,030 over the last ninety days. Corporate insiders own 6.97% of the company’s stock.
Regeneron Pharmaceuticals News Roundup
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
- Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
- Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
- Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
